Literature DB >> 11314753

Triiodothyronine predominant Graves' disease in a South-East Asian population: prevalence and clinical significance.

A M Yong, E S Tai, Z W Wong, P H Eng, S C Ho, D H Khoo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11314753     DOI： 10.1007/BF03343845

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  5 in total

1.  Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.

Authors:  J J Chen; P W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  1986-07       Impact factor: 5.958

2.  Thyroid stimulating immunoglobulins in Graves' disease with goitre growth, low thyroxine and increasing triiodothyronine during PTU treatment.

Authors:  L Hegedüs; J M Hansen; K Bech; J P Kampmann; K Jensen; E Andersen; P Hansen; S Karstrup; H Bliddal
Journal:  Acta Endocrinol (Copenh)       Date:  1984-12

3.  Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves' disease.

Authors:  J Takamatsu; M Sugawara; K Kuma; A Kobayashi; F Matsuzuka; T Mozai; J M Hershman
Journal:  Ann Intern Med       Date:  1984-03       Impact factor: 25.391

4.  Differential control of type-I iodothyronine deiodinase expression by the activation of the cyclic AMP and phosphoinositol signalling pathways in cultured human thyrocytes.

Authors:  S G Beech; S W Walker; J R Arthur; D Lee; G J Beckett
Journal:  J Mol Endocrinol       Date:  1995-04       Impact factor: 5.098

5.  Syndrome of persisting thyroid stimulating immunoglobulins and growth promotion of goiter combined with low thyroxine and high triiodothyronine serum levels in drug treated Graves' disease.

Authors:  K W Wenzel; J R Lente
Journal:  J Endocrinol Invest       Date:  1983-10       Impact factor: 4.256
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.